Lexicon Pharmaceuticals, Inc. announced on March 28, 2025, an exclusive worldwide license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate for obesity and associated metabolic disorders. This agreement grants Novo Nordisk exclusive global rights to develop, manufacture, and commercialize LX9851 in all indications.
Under the terms of the agreement, Lexicon is eligible to receive upfront and near-term milestone payments of up to $75 million. The total potential development, regulatory, and sales milestone payments could reach $1 billion, in addition to tiered royalties on net sales of LX9851.
Lexicon will complete agreed-upon Investigational New Drug (IND) application-enabling activities for LX9851, with Novo Nordisk responsible for the IND filing and all subsequent development, manufacturing, and commercialization. This partnership significantly strengthens Lexicon's financial position and validates its R&D portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.